Financial News

Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY). After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of fundamentals. Here is where I land on the $1,000 debate. The 24/7 Wall St. Price Target for Eli Lilly Eli Lilly trades at $948.45 as ... Eli Lilly Price Prediction: This Is Where The Stock Will End This Year

These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare.

Moby summary of Hims & Hers Health, Inc.'s Q1 2026 earnings call

Trinity, a leader in strategy, insights and analytics for the life sciences industry, announced the winners of the TGaS Advisors Best of Benchmark (BoBs) Awards. The awards, presented annually, recognize operational excellence across pharmaceutical organizations based on TGaS benchmarking data.

A spike in facility sales to outsourcing companies points to an industry need for greater flexibility.

The market adage “Sell in May and Go Away” rarely fits a single name cleanly. Eli Lilly (NYSE: LLY) is an unusual exception this spring. The GLP-1 leader has ripped higher off its post-earnings lows yet remains underwater for the year, an asymmetric setup that draws seasonal traders toward a tactical trim. The Setup: A ... Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom

Roche secured European CE Mark approval for its Elecsys pTau217 Alzheimer's blood test developed with Eli Lilly.

Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.

"I don't understand how this thing could have fallen so fast," the Mad Money host said of the medical device maker.

Shares of Hims & Hers Health fell 15% premarket on Tuesday after the telehealth company missed Wall Street estimates for first-quarter revenue and posted a surprise loss, hurt by changes in its...

Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for millions of patients around the world.1,2,5While maintaining accuracy comparable to spinal fluid diagnostics against the gold standard PET-CT scans, the Elecsys® pTau217 test offers a more convenient, minimally invasive alternative via a routine blood draw.1,2,4,7,8,11Diagnosing d

Elecsys pTau217 is the first blood test for Alzheimer's disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for

Eli Lilly's Omvoh (mirikizumab) has shown durable disease clearance over four years in patients with moderately to severely active ulcerative colitis. The long term data adds to existing evidence on Omvoh's efficacy and safety in inflammatory bowel disease. The results reinforce Eli Lilly's position in immunology and provide new information for clinicians and patients considering chronic treatment options. Eli Lilly (NYSE:LLY) enters this update with Omvoh's four year results adding another...

Exploring PRIMECAP Management (Trades, Portfolio)'s Recent 13F Filing and Investment Strategies

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Eli Lilly and Company is one of the best cancer stocks. TheFly reported on May 5 that Barclays increased its valuation outlook for LLY, raising the price target to $1,400 from $1,350 while maintaining an Overweight rating. The […]

The tech sector has a record-high market cap of over $23 trillion, a 37% weighting in the S&P 500, the largest percentage ever.

'Mad Money' host Jim Cramer weighs in on stocks including: Nokia, Chewy, Ford, Eli Lilly, Caterpillar, and more.

Eli Lilly faces challenges in the GLP-1 market, with Novo Nordisk gaining a timing advantage in both injectable and oral drug approvals.

If it feels like growth stocks can’t continue their outperformance much longer, ignore that feeling. The Vanguard S&P 500 Growth Index Fund Exchange-Traded Fund, home to companies with high sales growth including Nvidia Advanced Micro Devices Microsoft and Eli Lilly is up 13% in the past month. A couple of factors have driven the performance of the growth stocks.

Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Eli Lilly CFO Lucas Montrace joins Ashley Mastronardi on NYSE Live to discuss his YOY Revenue Beat

Eli Lilly pausedits obesity awareness campaign in India after the nation's drugsregulator warned the company it could violate rules againstadvertising prescription medicines to consumers even...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.